Anthem Biosciences Q1 FY27 earnings call
In brief
Anthem Q1 FY27 revenue ₹418 cr down 22.6% YoY on customer delivery timing; EBITDA margin 39.6%, FY27 growth intact.
- Management's tone
- Confident
- What was said
- Leaned positive
- Guidance
- Guidance held
- Analyst pushback
- Low
- Stock, next session
- −1.60% (Nifty 50 −0.79%)
- Q1 FY27 consolidated revenue ₹418 cr, down 22.6% YoY on customer delivery timing shifts to later quarters; CRDMO contributed ₹341 cr (81.5%) and Specialty Ingredients ₹78 cr (18.5%).
- EBITDA ₹176 cr (39.6% margin including other income of ₹25 cr); PAT ₹120 cr with margin 27.1%, both margins improved YoY despite top-line softness.
- 60% of FY27 order book already in hand after Q1; management expects Q1 to be the softest quarter with growth from Q2 onwards.
- Unit 4 Phase 1 capex of ₹1,200 cr over FY27-28 (FY27 ~₹700 cr, FY28 ~₹500 cr) adds 365 KL custom synthesis and 100 KL fermentation; commissioning targeted by end FY28.
- One new Big Pharma customer added; Semaglutide commercial supply awaiting CDSCO approval which management expects in 1-2 quarters.
An AI read of the company's transcript · the filing
The numbers
The quarter, Q1 FY27
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹418 cr | −22.6% | −31.5% | |
| EBITDA (excl. other income) | ₹151 cr | −21.4% | −43.9% | 36% (35.4% a year ago) |
| Net profit | ₹0 cr | — | — | 0% (0% a year ago) |
| EPS (₹) | ₹2.13 | −12.3% | — |
From the company's filed results for the quarter ended 30 Jun 2026 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
Where management's figures differ from the filing
- EBITDA: said ₹176 cr with margin 39.6% (INCLUDING other income of ₹25 cr); filed ₹150.57 cr with margin 36.0% (EXCLUDING other income). Management explicitly stated EBITDA 'includes other income'; filed figure is EBITDA excluding other income per disclosed formula.
What moved the numbers, as management explained it
- Customer delivery timing shifted to later quarters; customers rebalanced across geographies after missing projected launches in some markets — this is the principal driver of the YoY decline.
- Reported EBITDA of ₹176 cr (39.6% margin) includes ₹25 cr of other income; stripping this gives ~₹151 cr (~36% margin) — investors must not extrapolate the 39.6% figure. (accounting)
- Q1 effective tax rate was lower; FY27 full year expected to normalize to 25-25.5% as Neo Anthem (Unit 3 subsidiary) approaches break-even — Q1 PAT benefit is unlikely to repeat. (one-off)
- ESOP cost Q1 ₹2.25 cr; FY27 ~₹9 cr vs FY26 ~₹16 cr — the ESOP step-down reduced PAT drag versus prior year.
- Unit 3 (Neo Anthem) utilization ramped to 30-35% in Q1 FY27 from ~15% in FY26, contributing incremental revenue but still absorbing fixed costs.
The numbers management led with
- Order book visibility for FY27: 60% of full-year order book already in hand
- Unit 4 Phase 1 capex: Rs 1,200 crores over FY27-FY28 (50-50 split)
- Net cash position: Rs 1,720 crores as of June 30, 2026
- Neo Anthem (Unit 3) capacity utilization: 30-35% in Q1 FY27 vs ~15% in FY26 full year
Guidance
Guidance on this call
| What | For | What management said |
|---|---|---|
| Unit 4 Phase 1 capex FY27 | FY27 | FY27 targeted capex for this year will be close to about Rs. 700 crores |
| Unit 4 Phase 1 capex FY28 | FY28 | could be a 50-50 split across both these years, FY27 and FY28 |
| FY27 normalized tax rate | FY27 | we will have a much more marginalized tax rate of about 25% to 25.5% for this full year |
| ESOP cost FY27 | FY27 | ESOP cost is about Rs. 9 crores for FY27 |
| ESOP cost FY28 | FY28 | fourth-year ESOP charge will be about closer to about Rs. 5 crores next year |
| Employee cost as % of sales FY27 | FY27 | we will be largely around 13% sort of number as a percentage of sales |
| Other expenses as % of sales FY27 | FY27 | full year number trajectory will be in that 9% to 10% range |
| Unit 4 Phase 1 capacity addition | FY28 | we'll be adding about 365 kiloliters of custom synthesis, 100 kiloliters of fermentation |
| Unit 4 Phase 1 commissioning | FY28 | by end of FY28 is when we'd be ready with our Unit 4 expansion |
What changed since the Wed 20 May 2026 call
| What | On the Wed 20 May 2026 call | On this call |
|---|---|---|
| FY27 revenue growth aspiration (restated) | ~20% aspiration consistent with 10-year historical track record (FY27 onward) | Growth prospects intact, in line with historical performance; declined to give any specific percentage |
| FY27-FY28 Unit 4 Phase 1 capex (held) | FY27 ~Rs. 700 cr; FY28 ~Rs. 500 cr (Unit 4 Phase 1) | FY27 ~Rs. 700 cr; FY28 ~Rs. 500 cr; 50-50 split reaffirmed |
| Unit 4 Phase 1 commissioning (held) | Phase 1 completion towards latter half of March 2028 (H2 FY28) | By end of FY28 (March 2028) commissioning targeted; civil work nearly complete |
| Specialty ingredients growth (restated) | ~20% growth trajectory (FY27 onward) | Decent growth expected by year-end (qualitative only); ~20% not restated |
| EBITDA margin band (held) | 38-40% sustained going forward (FY27 onward) | Q1 delivered 39.6% margin (incl. other income); defended as sustainable through technology and cost discipline |
| GLP-1 Semaglutide commercial supply (delayed) | Biosimilar asset on track for FY27 P&L contribution; in discussions with all major players | Still awaiting CDSCO approval; expects clearance in next 1-2 quarters; no P&L contribution yet |
| New Big Pharma customer onboarding (new) | Focus on broadening top-20 big pharma relationships; lateral entry noted | One new Big Pharma customer added; agreement in works; expected to yield significant numbers |
Guided on earlier calls, and what was filed
| What | For | Guided | Filed |
|---|---|---|---|
| EBITDA margin | FY26 | at least 38% (on the Q1 FY26 call) | 38.1%, within the range |
| EBITDA margin (normalized, excl FX) | FY26 | 36–37% (on the Q2 FY26 call) | 38.1%, above the range |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
The business
By business
CRDMO
Revenue ₹341 cr (81.5% of total); Q1 saw delivery deferrals to later quarters; 60% of FY27 order book in hand; new Big Pharma customer added.
Revenue ₹341 cr (81.5% of total) · Unit 1 utilization ~78% · Unit 2 utilization ~50% · Unit 3 utilization 30-35% · Unit 4 Phase 1: +365 KL custom synthesis, +100 KL fermentation
Outlook: Q1 is the softest quarter; growth from Q2 onwards; 10 late-phase molecules targeted; Unit 4 commissioning by end FY28
Specialty Ingredients
Revenue ₹78 cr (18.5% of total); softer quarter on domestic raw-material supply chain pressures; decent growth expected by year-end.
Revenue ₹78 cr (18.5% of total)
Outlook: Decent growth by year-end despite raw-material supply chain pressures
Balance sheet, capex and funding
- Net cash position ₹1,720 crores as of June 30, 2026 — no debt flagged.
- FY27 capex ~₹700 crores; FY28 capex ~₹500 crores (Unit 4 Phase 1, 50-50 split reaffirmed).
- Working capital broadly stable: receivables down from Q4 peak (Q1 softer quarter); modest inventory build-up for Q2-Q3 raw materials; payables up correspondingly.
- Unit 4 Phase 1 civil work nearly complete; equipment orders being placed now.
The industry, as management sees it
Management frames CRDMO industry growth as robust with lumpiness at the quarterly level driven by customer-side global rollout logistics, regional approval timing and redistribution of materials across geographies. On AI in pharma: management views current narrative as mostly hype with thin use cases; anticipates real productivity gains in document review, antigen/target prediction (which would expand the funnel of work for CRDMOs) and manufacturing automation over the next 3-4 years. Anthem explicitly does not follow a patent-expiry-driven biosimilars playbook and only takes such work when approached by customers.
Risks management named
- Quarterly lumpiness in CRDMO business tied to customer delivery schedules and global rollout logistics
- Q1 FY27 customer delivery deferment pushed to H2 FY27 — YoY comparison framed as the right base
- Specialty ingredients raw material supply chain pressures from war/geopolitical disruption
- PAT likely to be depressed when Unit 4 investment phases in and Neo Anthem scales up
- Customer-side M&A can reshape project economics despite typical 1-2 year operational continuity post-close
Q&A
Discussion was dominated by capacity utilisation, Unit 4 capex articulation, customer-mix commentary (new Big Pharma win, biotech acquired by Big Pharma) and margin sustainability. Pushback was light and mostly on QoQ interpretive frameworks (Bino on 20%, Mehul on growth, Udit on deferment reasons); on the harder quantitative items (FY27 capex Rs 700 cr, Unit 4 Rs 1,200 cr, tax rate 25-25.5%) management gave direct numbers. The most notable deflection was Gawir declining to anchor a specific FY27 growth % despite prior history of ~20%. A standalone late-stage Q&A from Sajal Kapoor drew unusually candid commentary from the CEO on competitive positioning.
Not answered directly
- Specific FY27 revenue growth % guidance (declined to anchor beyond historical performance framing)
- Specific timeline for US FDA / European regulatory inspection of Unit 3
- Long-term gross margin trajectory beyond 2-3 years
Asked for a number, answered without one
- GLP-1 Semaglutide API commercial revenue: Awaiting CDSCO approval; sampled all major players; expects approval within 1-2 quarters; no specific revenue target given.
- Specialty ingredients FY27 growth: Decent growth expected by year-end but no specific percentage given; previous 20% trajectory not restated.
- New Big Pharma customer revenue contribution: Expected in later quarters of FY27; agreement not yet signed; described as multi-dimensional engagement — no specific revenue figure.
Every question, with its answer
1. Capacity utilisation & new clients
Saion Mukherjee, Nomura Group
Question. Can you update on capacity utilisation at Unit 1, 2 and Neo Anthem in Q1 and how utilisation should change over the next 3 years? Any timeline for regulatory inspection of Unit 3 by US FDA or European authorities? Are there updates on new contracts, new client traction including peptides?
Answer, Gawir Baig, Chief Financial Officer. Unit 1 ~78% utilised in Q1 FY27 (vs 74% full year FY26). Unit 2 ~50% in custom synthesis (expanded with ~130 KL addition); fermentation ~50% across 140 KL. Neo Anthem (Unit 3) at 30-35% in Q1 vs ~15% in FY26 — clear ramp-up. All three units expected to be completely full over the next 2 years; Unit 4 under construction to add 365 KL custom synthesis + 100 KL fermentation for commissioning by end of next year. On Unit 3 regulatory: no specific inspection timeline was articulated; the team did not commit to a date. On new clients: one new Big Pharma added, expected to yield significant numbers later in FY27; one large biotech customer recently acquired by a Big Pharma. Neo Anthem houses the modern pilot plant, peptide synthesis and oncology manufacturing, with new projects landing there.
Follow-up. Is increased utilisation at Neo Anthem mostly shifting production from existing units or new orders? Any timeline for when the new Big Pharma traction shows up? Existing commercial project or new molecule?
Answer. Mostly new orders, not just shifting; modern pilot plant, peptide synthesis and oncology manufacturing. Big Pharma should materialise in latter quarters of FY27; agreement being finalised. Multi-dimensional engagement spanning R&D, new projects and supply-chain diversification.
Not answered directly.
2. Order book visibility
Udit Bokaria, Catamaran
Question. At the start of Q1 is the 60% visibility for next quarter or the full year? Can you bifurcate the remaining 40% — what is the visibility in manufacturing vs R&D vs specialty ingredients?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. The 60% visibility refers to the full year, not just next quarter. Specialty ingredients is an ongoing B2B India business with rolling 3-6 month forecasts; some large customers give full-year forecasts. R&D contracts come in quarter by quarter at contract signing. The 60% order book concept largely applies to CRDMO; even after Q1 the order book has been replenished back to 60%. Clarified by CFO that the 60% is for the whole business, not just CRDMO.
Follow-up. Is the remaining 40% coming from new clients or existing customers increasing volumes? Where are we on lateral projects and already-commercialised molecules with the recently-onboarded Big Pharma — have they audited and signed? And are we going after biologic drugs going off-patent as a drug substance supplier?
Answer. It's a mix of both — new customer onboarding (some unknown % of sales) plus existing customers asking for extra volumes (a recent PO for incremental material was factored in). Lateral entry: a Big Pharma sent inquiries for existing products; for the Big Pharma on-boarded last quarter, advanced intermediates and starting materials inquiries have begun. Relationships mature over 3-4 years. On biosimilars/generics: Anthem does NOT follow a patent-expiry-driven playbook — only takes such work when customers approach, primarily in ADCs, off-patent mAbs and peptides.
3. Pipeline depth & FY27 growth
Mehul Sheth, HDFC Securities
Question. On the pipeline of liquid molecules — 100+ active projects with 10 in late phase — how many are in GLP or ADC segments? Any near-term visibility on commercialisation? And on Unit 4, what is the current status, capex already incurred, capex outlay for next 2 years and commissioning timeline? Also Q1 is down ~25% YoY — how do you see CRDMO for the full year?
Answer, Gawir Baig, Chief Financial Officer. 100+ early-stage programs, 10 in late phase. Path to commercialisation 18-24 months; customers commercialised 4 new molecules last year. On modalities: a couple of ADC molecules are in late phase; peptides are mostly early-stage. On FY27 outlook: growth prospects intact, order book full, Q2/Q3/Q4 expected to show recovery — lumpiness is the nature of CRDMO. Guidance is YoY, not QoQ. On Unit 4: ~Rs 1,200 cr Phase 1 capex; 30-acre property, Phase 1 uses half; adds 365 KL custom synthesis + 100 KL fermentation + food/nutra plant; ground broken last year, equipment orders going in now, ready by end FY28 with ~50-50 capex split across FY27 and FY28. Civil work nearly complete.
4. Capex, growth & tax
Bino Pathiparampil, Elara Capital
Question. What will be the total capex for FY27? Because of Unit 4, capex will stay elevated in FY28 and then come down — correct? Do you still maintain the targeted growth rate of 20% for FY27? When does the tax rate normalise to ~25%?
Answer, Gawir Baig, Chief Financial Officer. FY27 capex targeted close to Rs 700 cr. Correct on FY28 elevation and subsequent normalisation. On growth: not giving a specific % guidance, but historical 10-year healthy growth rate will continue into FY27. Effective tax rate should normalise to 25-25.5% for FY27 — FY26 was elevated because of losses at Neo Anthem; Neo Anthem expected to turn break-even to profitable this year on a full-year basis.
Not answered directly.
5. Semaglutide, margins & ESOP
Bansi Desai, JP Morgan
Question. Have we started commercial supply of Semaglutide API to domestic players? With a peer facing scaling-up issues on the API side, are we seeing more inbound from domestic players? What gives confidence that industry-high margins can be maintained over 3-5 years? Please quantify the ESOP cost for FY27 and where it goes after that.
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Semaglutide commercial supply not yet started. All scale-up and trial work done; awaiting CDSCO approval. Sampled nearly all large players who are waiting for the approval to issue POs; expects approval in a quarter or two. Anthem said it is NOT positioned opportunistically as a result of peer scaling issues — would be ready to service if opportunity arises. On margins: 60% order book in hand plus known cost structure defends this year's margin; technology moat (flow chemistry, bio-catalysis) helps cut cost of goods while retaining margins. Material margin increased in Q1 even on muted revenue. New unit ramp will cause PAT dips but management is confident of defending margins over 2-3 years. On ESOP: ~Rs 9 cr for FY27 (Q1: Rs 2.25 cr) vs Rs 16 cr FY26; FY28 ~Rs 5 cr as the year-4 charge. Decline is structural.
6. Customer M&A impact
Vivek Agarwal, Citi Group
Question. With one large biotech customer acquired by a Big Pharma — any expected change in demand for the projects with this customer? Have you worked with the Big Pharma acquirer before?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Constant M&A on customer side. Impact not material for the rest of this year. Acquisitions typically leave acquired team untouched for 1-2 years before volume ramp-up. Initial letter received, no meaningful discussions with acquirer yet. The business is sticky because it is highly regulated. The acquirer Big Pharma had no meaningful business with Anthem previously — the deal gives Anthem a foot in the door, which is a playbook Anthem has seen succeed in the past.
7. Contract nature & working capital
Tushar Manudhane, Motilal Oswal Financial Services
Question. On the existing customer contract — was it a manufacturing commercial contract or a scale-up for product approval? Is Anthem building capacity for the eventual commercial scale — would that require dedicated capacity? On working capital, any notable changes recently?
Answer, Gawir Baig, Chief Financial Officer. It is a development contract with the emerging biotech acquired by a Big Pharma — NOT commercial. Late Phase 3 development work; could be near commercialisation or still 1-2 years away. Phase 3 quantities have been supplied from Unit 1 and Unit 2. Unit 4 expansion largely caters to growth in the 14 commercial molecules plus the 10 late-phase programs likely to add commercial kits; no dedicated product facility built. Working capital in normal course — receivables crystallised from Q4, slight inventory build-up for Q2-Q3 RM procurement, payables up correspondingly. H1 FY27 balance sheet in line with H1 FY26.
8. Other expenses & cost structure
Vivek Agarwal, Citi Group
Question. We see muted trend in other expenses — any one-off, or is the discipline on cost-efficiency/yield optimisation recurring for FY27 and beyond?
Answer, Gawir Baig, Chief Financial Officer. No one-off in other expenses. Cost optimisation is structural across three metrics: (i) RM margin via yield improvement and backward integration of key intermediates; (ii) employee cost, amongst industry-lowest as % of sales — Q1 at 18.8% on muted revenue, FY27 should be ~13%; (iii) other expenses ~9-10% on full-year FY27 basis (Q1 was 8.2%).
9. Q1 trajectory & specialty ingredients
Dhaval Khut, Jefferies
Question. Is Q1 the lowest quarter this year — can we expect QoQ growth from Q2? Specialty ingredients also softer — when does it return to growth? Beyond CDSCO, what other markets is Anthem targeting for Semaglutide, and has regulatory work started?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Q1 is the softest quarter — only growth expected from here. Specialty ingredients has faced raw material turmoil (war, supply chain) but Anthem expects decent growth by year-end with visibility in hand. On Semaglutide: regulatory work has started but ONLY India is the priority; first gate is CDSCO approval expected in 1-2 quarters. Customers have been sampled overseas but everyone is waiting for Indian approval. GLP-1 remains a long-term robust opportunity for Anthem.
10. AI in CRDMO
Saion Mukherjee, Nomura Group
Question. AI is being discussed across biotech/pharma — what use cases is Anthem seeing today, and how might AI structurally impact Anthem's financials over a 5-year horizon?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Evolving landscape; largely 'hype' today, separating real from hype takes time. Use cases being explored: QA document review (fact-check automation), AI-driven antigen/target prediction (would create more targets — Anthem would benefit since lab work still needed), and manufacturing automation for resource/facility optimisation. Even large pharma customers give vague answers on their internal AI use. Anthem is actively seeking use cases over the next 3-4 years; will not miss the opportunity.
Partly answered.
11. Recently commercialised molecules
Parth Sodha, Trinetra Asset Management
Question. How are the four recently commercialised molecules progressing versus expectations?
Answer, Gawir Baig, Chief Financial Officer. Decent sales were achieved in March 2026 on these molecules. The order book for FY27 shows growth versus March 2026 levels on these recent commercialised products. Penetration into markets where innovators have launched takes couple of years before sizable supply volumes come in.
12. Deferment dynamics
Udit Bokaria, Catamaran
Question. What are the usual reasons a product growing YoY sees delivery deferment by the customer?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Customers serve global markets and project demand by geography; when actual offtake misses projection they reroute material and exhaust stock in slower markets before accepting new supply. Approvals also slip in some geographies, which delays intake. Confirmed orders are honoured; the redistribution (and sometimes re-routing of shipments between geographies) can affect quarterly numbers without affecting overall business. This is structural in CRDMO.
13. Competitive differentiation
Sajal Kapoor, Antifragile Thinking
Question. With Anthem expanding into multiple advanced modalities, what do customers value most when choosing Anthem over other CRDMOs — top 2 factors? As the platform broadens, which capability benefits most, and which becomes the hardest to preserve?
Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Top factors customers value: (1) keeping promises over the long term; (2) innovation contribution — bringing IP, not just acting as a pair of hands; (3) regulatory compliance track record; (4) manufacturing quality; (5) people quality — customers engage with scientists on the shop floor. Anthem's 360-degree training is a real differentiator. On expansion: the commodity half-life keeps shrinking (specialty to fine chemicals to commodity faster than before). Differentiation comes from innovation that widens the moat and rapid in-housing of new modalities. Hardest to preserve is the sharpness of differentiation as the industry evolves — Anthem is very mindful of this.
What was said
Topic by topic, in the order it was spoken
Q1 FY27 Financial Performance · Ajay Bhardwaj (MD & CEO)
- Consolidated revenue from operations Rs 418 cr; CRDMO Rs 341 cr (81.5%), Specialty Ingredients Rs 78 cr (18.5%)
- EBITDA Rs 176 cr (39.6% margin including other income); EBIT includes Rs 25 cr of other income
- PBT Rs 145 cr; PAT Rs 120 cr; PAT margin 27.1%; net cash Rs 1,720 cr as of June 30, 2026
- YoY improvement delivered in both EBITDA and PAT margins despite soft top line
Business Commentary & FY27 Outlook · Ajay Bhardwaj (MD & CEO)
- Q1 framed as timing shift in key customer deliveries; underlying demand described as strong
- Higher concentration of scheduled deliveries expected in H2 FY27
- Committed to sustaining revenue growth aligned with long-term historical performance
- Margin defence articulated via cost discipline, yield optimisation and employee productivity
In their words
Stay invested and if you haven't, please buy Anthem.
Don't worry about QoQ deliveries being lower or higher. Business is intact and we will continue to deliver on our growth numbers for FY27 as well.
Our Q1 FY27 results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, with a higher concentration of scheduled deliveries in the latter half of the year.
To check next time
What management committed to on this call, or the dates they gave.
- Q2 FY27 revenue ramp-up — management expects Q1 to be softest quarter with growth from Q2 onwards.
- CDSCO approval for Semaglutide API — management expects clearance within 1-2 quarters.
- Signing of new Big Pharma customer agreement and initial order flow.
- Unit 4 Phase 1 capex progress and equipment order placement (civil nearing completion).
- Specialty ingredients recovery from raw-material supply chain pressures.
- Effective tax rate trajectory toward 25-25.5% FY27 normalized range as Neo Anthem approaches break-even.
Transcript
Read along with the recording
The whole call, 110 lines from 14 speakers. Click any line to hear it, jump to the Q&A, or find a word. Free with an account.
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Wed 22 Jul 2026 | ₹778.90 | −1.60% | −0.79% |
| 5 sessions Tue 28 Jul 2026 | ₹783.90 | −0.97% | −0.84% |
| 20 sessions Tue 18 Aug 2026 | ₹891.05 | +12.57% | −0.14% |
From the close of Tue 21 Jul 2026, ₹791.55: the last close before the call, which began at 11:30 IST. Adjusted daily closes; the move includes everything else that happened in those sessions.